ClinicalTrials.gg
CompletedNCT03191136Updated Jan 16, 2019

Clinical Trial to Assess the Effect of Food on the Pharmacokinetics of YHD1119 in Healthy Volunteers

A Phase 1 interventional study of YHD1119 300mg and YHD1119 300mg in Peripheral Neuropathic Pain, sponsored by Yuhan Corporation. Completed at 1 site in Korea, Republic of. Open to male participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-01-16.

Sponsored by Yuhan Corporation · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
19 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 38 studies in Neuralgia with a site in Korea, Republic of — 2 open to participants now, 2 under way, none of them phase 3. Neuralgia · Korea, Republic of.

Enrollment
25th of 34
24 · median 90
Started
2017
with 4 others
Phase 1
8 of 38
none open now
Registered
19th of 38
by date
Lead sponsor
3 of 38
Yuhan Corporation

Among the 38 studies in Neuralgia with a site in Korea, Republic of, this one is the 25th largest by enrollment of the 34 interventional ones that give a count, is one of 5 that started in 2017, is one of 8 in phase 1, and was the 19th registered.

Neuralgia

1,102 studies on the registry are indexed under Neuralgia; 242 are open to participants now.

Browse Neuralgia studies →

Open to participants now

2 of the 38 studies in Neuralgia with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 153 Neuralgia studies recruiting now, 77 (50%) set no upper age limit and 44 (29%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 19 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Neuralgia with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This is a phase 1, open-label, randomized, single dose, crossover clinical trial to assess the effect of food on the pharmacokinetics of YHD1119 in healthy male volunteers.

Hypothesis: "YHD1119" is showing equal equal pharmacokinetics in fasted and fed state.

Read the detailed description

This is a phase 1, open-label, randomized, single dose, crossover clinical trial to assess the effect of food on the pharmacokinetics of YHD1119 in healthy male volunteers.

Group 1: 12 subjects will be assigned and they will be administered YHD1119 in fasted state at Day 1 and in fed state at Day 8.

Group 2: 12 subjects will be assigned and they will be administered YHD1119 in fed state at Day 1 and in fasted state at Day 8.

03

Conditions studied

  • Peripheral Neuropathic Pain

Browse trials for

04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male with (BMI) between 18.5 and 30 kg/m2
  • Who has not suffered from disease
  • Provision of signed written

Exclusion criteria

Exclusion Criteria:

  • History of and disease
  • A history of drug abuse or the presence of positive reactions to drugs that have abuse potential in urine screenings for drugs
  • Administration of other products within 3 months prior to the first dosing
  • Volunteers considered not eligible for the clinical trial by the investigator due to reasons including laboratory test results, ECGs, or vital signs
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Group1

    taking YHD1119 (pregabalin 300mg) in fasted state at Period 1

    Drug: YHD1119 300mg

  • Experimental
    Group2

    taking YHD1119 (pregabalin 300mg) in fed state at Period 1

    Drug: YHD1119 300mg

Interventions

  • DrugYHD1119 300mg

    Period 1:a single dose of YHD1119 300mg is administered in fasting condition Period 2:a single dose of YHD1119 300mg is administered in fed condition

  • DrugYHD1119 300mg

    Period 1:a single dose of YHD1119 300mg is administered in fed condition Period 2:a single dose of YHD1119 300mg is administered in fasting condition

06

What researchers measure

Primary outcomes

  1. YHD1119 Cmax

    Cmax

    Time frame: 0 - 36hrs

  2. YHD1119 AUC last

    AUC last

    Time frame: 0 - 36hrs

07

Study locations

1 site
  • Chonbuk National University Hospital
    Jeonju, 561-712, Korea, Republic of
08

References and documents

Publications

  • Moon SJ, Jeon JY, Lim Y, An T, Jang SB, Kim S, Na WS, Lee SY, Kim MG. Pharmacokinetics of a New, Once-Daily, Sustained-release Pregabalin Tablet in Healthy Male Volunteers. Clin Ther. 2021 Aug;43(8):1381-1391.e1. doi: 10.1016/j.clinthera.2021.06.010. Epub 2021 Jul 11. PubMed 34256964 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in Jun 2017, 1 month.

Of 36 phase 1 interventional studies under Neuralgia, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's 1 month is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2017
First posted
Jun 19, 2017
StartActual
May 10, 2017
Primary completionActual
Jun 27, 2017
CompletionActual
Oct 30, 2017
Last update
Jan 16, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03191136
Lead sponsor
Yuhan Corporation
Responsible party
Sponsor
First posted
Jun 19, 2017
Start date
May 10, 2017
Primary completion
Jun 27, 2017
Completion
Oct 30, 2017
Last update
Jan 16, 2019

Study contacts

Mingul Kim, MD
principal investigator · Chonbuk National University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion